Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
guys this co is killing it. 2 huge deals in 2 wks. they got $7 mil in cash on last deal plus stock and now another huge deal. next 10q will be a MONSTER. CO SO UNDERVALUED $$$$$$
Beautiful how these large spikers large pullbacks work. Take Some Profits and keep your shares volume
Well you got your news. Jumped to 1.78 now it pulled back to 1.32
WOW this Teeeeeiiiiiiiinnnnnnny little Float appears to be gaining some strength. Let's see how the Week Goes. NEWS could really Ignite this to the Upside.
You just like your Woke BFF still mad you stuck it out in that POS MONKEY TRAP. HAHAHAHAHAHAHAHAHAHA!!!!
Lolz what hat a pos
Is ABVC the Next TP$T on Steroids? Let's see how this goes as the NEWS Cycles through this little ticker over the Coming Weeks...
Taken a little bit of a position, This could Spike and move strongly as News Arrives. Aren't they Funded for a while?
LOL, well Let's see 2.00 dollars first.
Definitely 20/20 vision > " Zacks reports a $20.20 price target from an analyst "
ABVC BioPharma: A Comprehensive Guide To Discover The True Value Of Your Shares:
11/01/2023 7:45 P.M.
Key Highlights
• ABVC Biopharma has gained interest in the investment community due to strategic partnerships in neurological and mental health treatments.
• The company's CNS drugs targeting MDD and ADHD have definitive agreements and a licensing deal, with potential income of $20 million and a valuation of $667 million.
• ABVC's flagship product, Vitargus®, is expected to be the first biodegradable hydrogel product used in retinal detachment surgery, with positive results potentially leading to distribution agreements in Asia and Australia.
The story of a company changing the way we treat diseases
ABVC BioPharma, Inc. (NASDAQ: ABVC ), is a clinical-stage biopharmaceutical company with the aim of transforming the oncology/hematology, CNS disorders, and ophthalmology treatment landscape with healthier and innovative therapies with better odds at a positive outcome.
Pioneering the future of neurological and mental health treatments
ABVC Biopharma Inc. has recently gained interest in the investment community. The stock surged by 300% and then retreated on Thursday October 26, 2023 following the company's announcement of a term sheet to license global rights for CNS drugs targeting MDD and ADHD to AiBtl BioPharma for a valuation of $667 million. ABVC is excited about its major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive the multi-product biopharma company forward. ABVC has definitive agreements for the same CNS drugs with Xinnovation for ABV-1504, ABV-1505, and ABV-1601. The licensing deal carries a possible aggregate income of $20 million for ABVC. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. Xinnovation will fund the Phase III trials under the agreement and ABVC gets the global market less the Chinese market.
Xinnovation Therapeutics Co., Ltd. is headquartered in Hangzhou, China, with offices in the United States & Europe. The company has raised over $100 million in funding from leading investors, including Sequoia Capital China, Hillhouse Capital, & OrbiMed.
The ABVC collaboration holds immense potential for both companies.
ABVC, anticipates substantial royalty payments ranging from 5% to 12% based on the projected annual net sales of the licensed drugs in China. The deal could generate approximately $50 million annual revenue for ABVC, with an estimated revenue of $1 billion during the patent life of these products, could be achieved. Figures highlight the Chinese market potential.
ABVC's CNS drugs have been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, ABVC commenced the ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. The trials are heading for the interim report, which ABVC expects to complete by the end of 2023.
Vitargus®: A revolutionary hydrogel product for retinal detachment surgery
In ophthalmology, Vitargus® (ABV-1701) is a groundbreaking, advanced-staged and ABVC's flagship product that is expected to be the first biodegradable hydrogel product used in retinal detachment surgery. Vitargus® has completed the feasibility study in Australia and was approved by the Australian Therapeutic Goods Administration (TGA) to initiate the next phase of the trial in two participating sites.
The Science Park Administration in Taiwan approved ABVC’s plan to set up a pilot Good Manufacturing Practice (GMP) facility to produce Vitargus® and to pursue the process development work for manufacturing optimization. This project is proposed by ABVC’s Taiwan affiliate and co-development partner, BioFirst Corporation.
The Phase II trial of Vitargus® is expected to release its results in Q4 2023. If the results are positive, it could lead to distribution agreements in Asia and Australia in early 2024.
According to iHealthcare Analyst, Inc., the global market for retinal surgery devices is expected to reach $4.3 billion by 2029, driven, in part, by the rising geriatric population worldwide.
Early clinical studies done by the Company indicate Vitargus® has unique properties that could eliminate the need for patients to remain in a face-down position post-surgery, while significantly improving patient comfort and visual acuity during surgical recovery compared to current products available on the market. Vitargus® is believed to be the first biodegradable vitreous substitute to eliminate the need for an additional surgery to remove surgical fluids.Several large pharmaceutical companies are interested in becoming distribution and/or manufacturing partners for Vitargus®. ABVC continues to have active discussions.
FDA approves clinical trial of BLEX 404 for Advanced Non-Small Cell Lung Cancer
The U.S. FDA has approved the Investigational New Drug (IND) application for the proposed clinical investigation of BLEX 404, the primary active ingredient in ABV-1519. This treatment is being co-developed by BioKey, Inc. and by the Rgene Corporation, Taiwan. The study is under review at the Taiwan FDA for approval. With three previous INDs approved by the US FDA for combination therapies of triple-negative breast cancer, myelodysplastic syndromes (MDS), and pancreatic cancer, BLEX 404 is a promising new option in the fight against cancer.
Financial report with forward progress
ABVC BioPharma is making significant strides in its clinical trials and pipeline development thus creating a more financially sound company going forward under an experienced CEO. The company generated $969,783 and $355,797 in revenues for the years ended December 31, 2022 and 2021, respectively, representing an increase of $613,986 or approximately 173%.Despite a net loss of $16,312,374 for the year ended December 31, 2022 compared to $12,035,851 for the year ended December 31, 2021, ABVC BioPharma has received a $3.175 million investment from The Lind Partners to continue clinical trials. This investment will help the company to further develop its pipeline of six drugs and one medical device known as Vitargus®, a biodegradable vitreous substitute that facilitates retina reattachment surgery.
ABVC signed both an agreement with Xinnovation and a term sheet with AiBtl BioPharma to earn licensing fees of up to $20 million from Xinnovation and royalties of 5-12% of net sales from AiBtl BioPharma. The licensed products in the term sheet with AiBtl BioPharma for Major Depressive Disorder (MDD) and Attention-Deficit/Hyperactivity Disorder (ADHD) were valued at $667 million by a third-party evaluation. The new CEO of ABVC has chosen to forgo a salary and instead opted for stock options as a pivotal component of his compensation package. This move demonstrates the CEO’s confidence in the company’s future and its potential for growth.The future financial outlook looks to be improving dramatically for ABVC BioPharma with the flagship product Vitargus® expected to find cash infusion collaboration deals in the near future.
Forging powerful alliances with strategic partners to unlock new opportunities and drive growth
1) BioKey, Inc., a leading producer of dietary supplements in its GMP facility, is set to receive USD $1.0 million from Define Biotech Co. Ltd. amid increasing interest in mushroom-based nutritional supplements. Define Biotech has been granted the right to distribute the nutritional supplement containing Maitake mushrooms in China and Taiwan. Provides contract development and manufacturing services
.2) MerDury BioPharma for New Product Development and Commercialization through BioKey, Inc. collaborative agreement
3) Ramathibidi Hospital in Thailand. Update on Phase II site initiation
4) Srinagarind Hospital in Thailand Vitargus® meeting to discuss Phase II study protocol with the principal investigator and begin training clinical personnel. Agreement Update on Phase II site initiation
5) Sydney Eye Hospital in Australia Receives ethical approval
6) Cedars-Sinai Medical Center conducts some of the studies Phase I study treating depression
7) Rgene Corporation, Taiwan. Co-development partnership
8) AiBtl BioPharma $667 million deal Best Stocks. AiBtl is an American company and intends to go public on NASDAQ in 2024.
9) Xinnovation Licensing agreement Exclusive licensing agreement in China
10) Science Park Administration in Taiwan creating production facility
11) Zhonghui United Technology (Chengdu) Group Co., Ltd Cooperation Agreement to exchange a 20% ownership stake. Do not underestimate the culture for "healthy medicines" in China and all of Asia.
The list of strategic partnerships mentioned above is just the tip of the iceberg. The extensive network of partners is constantly growing and evolving to provide a bright future for investors and customers..
Video investors should not miss
The final word
ABVC Biopharma Inc. is a promising investment with multiple near-term catalysts. The company’s strategic partnerships in neurological and mental health treatments create a promising future. ABVC’s CNS drugs targeting MDD and ADHD have definitive agreements with Xinnovation for ABV-1504, ABV-1505 and ABV-1601, The definitive agreement carries a possible aggregate income of $20 million for ABVC. There is also a licensing deal with AiBtl BioPharma for a valuation of $667 million. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. ABVC’s CNS drug has been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
Investors should keep an eye on ABVC’s major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive its multi-product biopharma company forward. The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, ABVC has commenced ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. With all these developments in place, ABVC Biopharma Inc. is poised to make a significant impact in the biopharmaceutical industry. ABVC Biopharma shares could revalue upwards of $35 in 12 months, given the transformational leadership of the current CEO and his team.
Information concerning the derived price projection
The Marketing Sentinel Share price expected to rise
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet Buying while staying silent?
Previously Zacks had a $9.50 valuation before the current news releases.
Zacks reports a $20.20 price target from an analyst $20.20
Given the current direction of ABVC Biopharma under the leadership of its CEO, a $35 share projection in 12 months seems justified.
ABVC BioPharma: A Promising Investment Discover The True Value Of Your Shares: A Comprehensive Guide
11/01/2023 3:10 P.M.
Key Highlights
• ABVC Biopharma has gained interest in the investment community due to strategic partnerships in neurological and mental health treatments.
• The company's CNS drugs targeting MDD and ADHD have definitive agreements and a licensing deal, with potential income of $20 million and a valuation of $667 million.
• ABVC's flagship product, Vitargus®, is expected to be the first biodegradable hydrogel product used in retinal detachment surgery, with positive results potentially leading to distribution agreements in Asia and Australia.
The story of a company changing the way we treat diseases
ABVC BioPharma, Inc. (NASDAQ: ABVC ), is a clinical-stage biopharmaceutical company with the aim of transforming the oncology/hematology, CNS disorders, and ophthalmology treatment landscape with healthier and innovative therapies with better odds at a positive outcome.
Pioneering the future of neurological and mental health treatments
ABVC Biopharma Inc. has recently gained interest in the investment community. The stock surged by 300% and then retreated on Thursday October 26, 2023 following the company's announcement of a term sheet to license global rights for CNS drugs targeting MDD and ADHD to AiBtl BioPharma for a valuation of $667 million. ABVC is excited about its major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive the multi-product biopharma company forward. ABVC has definitive agreements for the same CNS drugs with Xinnovation for ABV-1504, ABV-1505, and ABV-1601. The licensing deal carries a possible aggregate income of $20 million for ABVC. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. Xinnovation will fund the Phase III trials under the agreement and ABVC gets the global market less the Chinese market.
ABVC's CNS drugs have been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, ABVC commenced the ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. The trials are heading for the interim report, which ABVC expects to complete by the end of 2023.
Vitargus®: A revolutionary hydrogel product for retinal detachment surgery
In ophthalmology, Vitargus® (ABV-1701) is a groundbreaking, advanced-staged and ABVC's flagship product that is expected to be the first biodegradable hydrogel product used in retinal detachment surgery. Vitargus® has completed the feasibility study in Australia and was approved by the Australian Therapeutic Goods Administration (TGA) to initiate the next phase of the trial in two participating sites.
The Science Park Administration in Taiwan approved ABVC’s plan to set up a pilot Good Manufacturing Practice (GMP) facility to produce Vitargus® and to pursue the process development work for manufacturing optimization. This project is proposed by ABVC’s Taiwan affiliate and co-development partner, BioFirst Corporation.
The Phase II trial of Vitargus® is expected to release its results in Q4 2023. If the results are positive, it could lead to distribution agreements in Asia and Australia in early 2024.
According to iHealthcare Analyst, Inc., the global market for retinal surgery devices is expected to reach $4.3 billion by 2029, driven, in part, by the rising geriatric population worldwide.
Early clinical studies done by the Company indicate Vitargus® has unique properties that could eliminate the need for patients to remain in a face-down position post-surgery, while significantly improving patient comfort and visual acuity during surgical recovery compared to current products available on the market. Vitargus® is believed to be the first biodegradable vitreous substitute to eliminate the need for an additional surgery to remove surgical fluids.Several large pharmaceutical companies are interested in becoming distribution and/or manufacturing partners for Vitargus®. ABVC continues to have active discussions.
FDA approves clinical trial of BLEX 404 for Advanced Non-Small Cell Lung Cancer
The U.S. FDA has approved the Investigational New Drug (IND) application for the proposed clinical investigation of BLEX 404, the primary active ingredient in ABV-1519. This treatment is being co-developed by BioKey, Inc. and by the Rgene Corporation, Taiwan. The study is under review at the Taiwan FDA for approval. With three previous INDs approved by the US FDA for combination therapies of triple-negative breast cancer, myelodysplastic syndromes (MDS), and pancreatic cancer, BLEX 404 is a promising new option in the fight against cancer.
Financial report with forward progress
ABVC BioPharma is making significant strides in its clinical trials and pipeline development thus creating a more financially sound company going forward under an experienced CEO. The company generated $969,783 and $355,797 in revenues for the years ended December 31, 2022 and 2021, respectively, representing an increase of $613,986 or approximately 173%.Despite a net loss of $16,312,374 for the year ended December 31, 2022 compared to $12,035,851 for the year ended December 31, 2021, ABVC BioPharma has received a $3.175 million investment from The Lind Partners to continue clinical trials. This investment will help the company to further develop its pipeline of six drugs and one medical device known as Vitargus®, a biodegradable vitreous substitute that facilitates retina reattachment surgery.
ABVC signed both an agreement with Xinnovation and a term sheet with AiBtl BioPharma to earn licensing fees of up to $20 million from Xinnovation and royalties of 5-12% of net sales from AiBtl BioPharma. The licensed products in the term sheet with AiBtl BioPharma for Major Depressive Disorder (MDD) and Attention-Deficit/Hyperactivity Disorder (ADHD) were valued at $667 million by a third-party evaluation. The new CEO of ABVC has chosen to forgo a salary and instead opted for stock options as a pivotal component of his compensation package. This move demonstrates the CEO’s confidence in the company’s future and its potential for growth.The future financial outlook looks to be improving dramatically for ABVC BioPharma with the flagship product Vitargus® expected to find cash infusion collaboration deals in the near future.
Forging powerful alliances with strategic partners to unlock new opportunities and drive growth
1) BioKey, Inc., a leading producer of dietary supplements in its GMP facility, is set to receive USD $1.0 million from Define Biotech Co. Ltd. amid increasing interest in mushroom-based nutritional supplements. Define Biotech has been granted the right to distribute the nutritional supplement containing Maitake mushrooms in China and Taiwan. Provides contract development and manufacturing services
.2) MerDury BioPharma for New Product Development and Commercialization through BioKey, Inc. collaborative agreement
3) Ramathibidi Hospital in Thailand. Update on Phase II site initiation
4) Srinagarind Hospital in Thailand Vitargus® meeting to discuss Phase II study protocol with the principal investigator and begin training clinical personnel. Agreement Update on Phase II site initiation
5) Sydney Eye Hospital in Australia Receives ethical approval
6) Cedars-Sinai Medical Center conducts some of the studies Phase I study treating depression
7) Rgene Corporation, Taiwan. Co-development partnership
8) AiBtl BioPharma $667 million deal Best Stocks. AiBtl is an American company and intends to go public on NASDAQ in 2024.
9) Xinnovation Licensing agreement Exclusive licensing agreement in China
10) Science Park Administration in Taiwan creating production facility
11) Zhonghui United Technology (Chengdu) Group Co., Ltd Cooperation Agreement to exchange a 20% ownership stake. Do not underestimate the culture for "healthy medicines" in China and all of Asia.
The list of strategic partnerships mentioned above is just the tip of the iceberg. The extensive network of partners is constantly growing and evolving to provide a bright future for investors and customers..
Video investors should not miss
The final word
ABVC Biopharma Inc. is a promising investment with multiple near-term catalysts. The company’s strategic partnerships in neurological and mental health treatments create a promising future. ABVC’s CNS drugs targeting MDD and ADHD have definitive agreements with Xinnovation for ABV-1504, ABV-1505 and ABV-1601, Thedefinitive agreement carries a possible aggregate income of $20 million for ABVC. There is also a licensing deal with AiBtl BioPharma for a valuation of $667 million. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. ABVC’s CNS has been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
Investors should keep an eye on ABVC’s major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive its multi-product biopharma company forward. The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, ABVC has commenced ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. With all these developments in place, ABVC Biopharma Inc. is poised to make a significant impact in the biopharmaceutical industry. ABVC Biopharma shares could revalue upwards of $35 in 12 months, given the transformational leadership of the current CEO and his team.
Information concerning on the derived price projection
The Marketing Sentinel Share price expected to rise
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet Buying while staying silent?
Previously Zacks had a $9.50 valuation before the current news releases.
Zacks reports a $20.20 price target from an analyst $20.20
Given the current direction of ABVC Biopharma under the leadership of its CEO, a $35 share projection in 12 months seems justified.
Disclaimer
I enjoy searching for undervalued micro caps (Invested in ABVC as it fits the profile). Over the years, I have become a biotech fanatic & studying biotech is my passion. All posts are to initiate discussion, definitely not financial advice.
WOOOOOOOOOOOW 29000 SHARE BUY $$$$$$$$$$$$$$$$4
ABVC BioPharma: A Promising Investment With a $35 Per Share Valuation target
11/01/2023 1:00 A.M.
Highlights
• ABVC BioPharma, Inc. (NASDAQ: ABVC), is clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system (CNS) disorders, and ophthalmology.
• ABVC Biopharma has gained interest in the investment community due to strategic partnerships in neurological and mental health treatments.
• The company's CNS drugs targeting MDD and ADHD have definitive agreements and a licensing deal, with potential income of $20 million and a valuation of $667 million.
• ABVC's flagship product, Vitargus®, is expected to be the first biodegradable hydrogel product used in retinal detachment surgery, with positive results potentially leading to distribution agreements in Asia and Australia.
About the company
ABVC BioPharma, Inc. (NASDAQ: ABVC), is clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system (CNS) disorders, and ophthalmology.
Promising future in neurological and mental health treatments
ABVC Biopharma Inc. has recently gained interest in the investment community. The stock surged by 300% and then retreated on Thursday October 26, 2023 following the company's announcement of a term sheet to license global rights for CNS drugs targeting MDD and ADHD to AiBtl BioPharma for a valuation of $667 million. ABVC is excited about its major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive the multi-product biopharma company forward. ABVC has definitive agreements for the same CNS drugs with Xinnovation for ABV-1504, ABV-1505, and ABV-1601. The licensing deal carries a possible aggregate income of $20 million for ABVC. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. Xinnovation will fund the Phase III trials under the agreement and ABVC gets the global market less the Chinese market.
ABVC's CNS drugs have been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, ABVC commenced the ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. The trials are heading for the interim report, which ABVC expects to complete by the end of 2023.
Vitargus®: A groundbreaking hydrogel product for retinal detachment surgery
In ophthalmology, ABVC’s Vitargus® (ABV-1701) is a groundbreaking, advanced-staged flagship product that is expected to be the first biodegradable hydrogel product used in retinal detachment surgery. Vitargus® has completed the feasibility study in Australia and was approved by the Australian Therapeutic Goods Administration (TGA) to initiate the next phase of the trial in two participating sites.
The Science Park Administration in Taiwan approved ABVC’s plan to set up a pilot Good Manufacturing Practice (GMP) facility to produce Vitargus® and to pursue the process development work for manufacturing optimization. This project is proposed by ABVC’s Taiwan affiliate and co-development partner, BioFirst Corporation.
The Phase II trial of Vitargus® is expected to release its results in Q4 2023. If the results are positive, it could lead to distribution agreements in Asia and Australia in early 2024.
According to iHealthcare Analyst, Inc., the global market for retinal surgery devices is expected to reach $4.3 billion by 2029, driven, in part, by the rising geriatric population worldwide.
Early clinical studies done by the Company indicate Vitargus® has unique properties that could eliminate the need for patients to remain in a face-down position post-surgery, while significantly improving patient comfort and visual acuity during surgical recovery compared to current products available on the market. Vitargus® is believed to be the first biodegradable vitreous substitute to eliminate the need for an additional surgery to remove surgical fluids.Several large pharmaceutical companies are interested in becoming distribution and/or manufacturing partners for Vitargus®. ABVC continues to have active discussions.
FDA approves clinical trial of BLEX 404 for advanced non-small cell lung cancer
The US FDA has approved the Investigational New Drug (IND) application for the proposed clinical investigation of BLEX 404, the primary active ingredient in ABV-1519. This treatment is being co-developed by BioKey, Inc. and by the Rgene Corporation, Taiwan. The study is under review at the Taiwan FDA for approval. With three previous INDs approved by the US FDA for combination therapies of triple-negative breast cancer, myelodysplastic syndromes (MDS), and pancreatic cancer, BLEX 404 is a promising new option in the fight against cancer.
Financials
ABVC BioPharma has been making significant strides in its clinical trials and pipeline development thus creating a more financially sound company going forward under an experienced CEO. The company generated $969,783 and $355,797 in revenues for the years ended December 31, 2022 and 2021, respectively, representing an increase of $613,986 or approximately 173%.Despite a net loss of $16,312,374 for the year ended December 31, 2022 compared to $12,035,851 for the year ended December 31, 2021, ABVC BioPharma has received a $3.175 million investment from The Lind Partners to continue clinical trials. This investment will help the company to further develop its pipeline of six drugs and one medical device known as Vitargus®, a biodegradable vitreous substitute that facilitates retina reattachment surgery.
ABVC has also signed both an agreement with Xinnovation and a term sheet with AiBtl BioPharma to earn licensing fees of up to $20 million from Xinnovation and royalties of 5-12% of net sales from AiBtl BioPharma. The licensed products in the term sheet with AiBtl BioPharma for Major Depressive Disorder (MDD) and Attention-Deficit/Hyperactivity Disorder (ADHD) were valued at $667 million by a third-party evaluation. The new CEO of ABVC has chosen to forgo a salary and instead opted for stock options as a pivotal component of his compensation package. This move demonstrates the CEO’s confidence in the company’s future and its potential for growth.The future financial outlook looks to be improving dramatically for ABVC BioPharma with the flagship product Vitargus® expected to find cash infusion collaboration deals in the near future.
Strategic partnerships
1)BioKey, Inc., a leading producer of dietary supplements in its GMP facility, is set to receive USD $1.0 million from Define Biotech Co. Ltd. amid increasing interest in mushroom-based nutritional supplements. Define Biotech has been granted the right to distribute the nutritional supplement containing Maitake mushrooms in China and Taiwan
.2)ABVC BioPharma has a collaboration agreement with MerDury BioPharma for New Product Development and Commercialization through BioKey, Inc.
3) Ramathibidi Hospital in Thailand. Press release
4) Srinagarind Hospital in Thailand Vitargus® meeting to discuss Phase II study protocol with the principal investigator and begin training clinical personnel. Agreement
5) Sydney Eye Hospital in Australia
6) Cedars-Sinai Medical Center conducts some of the studies
7) Rgene Corporation, Taiwan Rgene. Co-development partnership[color=red][/color]
8) AiBtl BioPharma $667 million deal
9) Xinnovation Licensing agreement
10) Science Park Administration in Taiwan creating production facility
11) Cooperation Agreement to exchange a 20% ownership stake in real estate property of Zhonghui United Technology (Chengdu) Group Co., Ltd. Health and wellness in China. Do not underestimate the culture for "healthy medicines" in China and all of Asia.
The above is not a full list of strategic partnerships as the list is extensive.
Conclusion
ABVC Biopharma Inc. is a promising investment with multiple near-term catalysts. The company’s strategic partnerships in neurological and mental health treatments create a promising future. ABVC’s CNS drugs targeting MDD and ADHD have definitive agreements with Xinnovation for ABV-1504, ABV-1505 and ABV-1601, Thedefinitive agreement carries a possible aggregate income of $20 million for ABVC. There is also a licensing deal with AiBtl BioPharma for a valuation of $667 million. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. ABVC’s CNS has been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
Investors should keep an eye on ABVC’s major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive its multi-product biopharma company forward. The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, ABVC has commenced ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. With all these developments in place, ABVC Biopharma Inc. is poised to make a significant impact in the biopharmaceutical industry. ABVC share could revalue upwards of $35 in 12 months given the transformation the CEO and his team are making at ABVC Biopharma.
4 mil cap. $7 mil in cash on new deal plus bunch of stock and potential $660 mil . at 1x is up 150x from here. lets buy co $$$
wow great stuff. stock should be way uppppppp $$$$$$$$$$$$$$$$$$. keep bring the great stuff. im buying more as sooooooooooo undervalued
ABVC BioPharma: A Promising Investment With Multiple Near-Term Catalysts
10/30/2023 8:20 PM EST
Strategic partnerships create a promising future in neurological and mental health treatments
ABVC Biopharma Inc (ABVC) has recently gained interest in the investment community. The stock surged by 300% and then retreated on Thursday October 26, 2023 following the company's announcement of a term sheet to license global rights for CNS drugs targeting MDD and ADHD to AiBtl BioPharma for a valuation of $667 million. ABVC is excited about its major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive the multi-product biopharma company forward. ABVC has definitive agreements for the same CNS drugs with Xinnovation for ABV-1504, ABV-1505, and ABV-1601. The licensing deal carries a possible aggregate income of $20 million for ABVC. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. Xinnovation will fund the Phase III trials under the agreement and ABVC gets the global market less the Chinese market.
ABVC's CNS drugs have been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, ABVC commenced the ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. The trials are heading for the interim report, which ABVC expects to complete by the end of 2023.
Vitargus®: A groundbreaking hydrogel product for retinal detachment surgery
In ophthalmology, ABVC’s Vitargus® (ABV-1701) is a groundbreaking, advanced-staged flagship product that is expected to be the first biodegradable hydrogel product used in retinal detachment surgery. Vitargus® has completed the feasibility study in Australia and was approved by the Australian Therapeutic Goods Administration (TGA) to initiate the next phase of the trial in two participating sites. The Science Park Administration in Taiwan approved ABVC’s plan to set up a pilot Good Manufacturing Practice (GMP) facility to produce Vitargus® and to pursue the process development work for manufacturing optimization. This project is proposed by ABVC’s Taiwan affiliate and co-development partner, BioFirst Corporation. The Phase II trial of Vitargus is expected to release its results in Q4 2023. If the results are positive, it could lead to distribution agreements in Asia and Australia in early 2024. According to iHealthcare Analyst, Inc., the global market for retinal surgery devices is expected to reach $4.3 billion by 2029, driven, in part, by the rising geriatric population worldwide.
FDA approves clinical trial of BLEX 404 for advanced non-small cell lung cancer
The US FDA has approved the Investigational New Drug (IND) application for the proposed clinical investigation of BLEX 404, the primary active ingredient in ABV-1519. This treatment is being co-developed by BioKey, Inc. and by the Rgene Corporation, Taiwan. The study is under review at the Taiwan FDA for approval. With three previous INDs approved by the US FDA for combination therapies of triple-negative breast cancer, myelodysplastic syndromes (MDS), and pancreatic cancer, BLEX 404 is a promising new option in the fight against cancer.
Here's a link for more information: LINK
In conclusion
ABVC Biopharma Inc. is a promising investment with multiple near-term catalysts. The company’s strategic partnerships in neurological and mental health treatments create a promising future. ABVC’s CNS drugs targeting MDD and ADHD have definitive agreements with Xinnovation for ABV-1504, ABV-1505 and ABV-1601, Thedefinitive agreement carries a possible aggregate income of $20 million for ABVC. There is also a licensing deal with AiBtl BioPharma for a valuation of $667 million. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. ABVC’s CNS has been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
Investors should keep an eye on ABVC’s major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive its multi-product biopharma company forward. The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, ABVC has commenced ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. With all these developments in place, ABVC Biopharma Inc. is poised to make a significant impact in the biopharmaceutical industry
ABVC BioPharma: A Promising Investment With Multiple Near-Term Catalysts
10/31/2023 8:20 PM EST
Strategic partnerships create a promising future in neurological and mental health treatments
ABVC Biopharma Inc (ABVC) has recently gained interest in the investment community. The stock surged by 300% and then retreated on Thursday October 26, 2023 following the company's announcement of a term sheet to license global rights for CNS drugs targeting MDD and ADHD to AiBtl BioPharma for a valuation of $667 million. ABVC is excited about its major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive its multi-product biopharma company forward. Investors should remember that ABVC has definitive agreements for the same CNS drugs with Xinnovation for ABV-1504, ABV-1505, and ABV-1601. The licensing deal carries a possible aggregate income of $20 million for ABVC. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. Xinnovation will fund the Phase III trials under the agreement and ABVC gets the global market less the Chinese market.
ABVC's CNS has been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, we commenced the ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. The trials are heading for the interim report, which we expect to complete by the end of 2023.
Vitargus®: A groundbreaking hydrogel product for retinal detachment surgery
In ophthalmology, ABVC’s Vitargus® (ABV-1701) is a groundbreaking, advanced-staged flagship product that is expected to be the first biodegradable hydrogel product used in retinal detachment surgery. Vitargus® has completed the feasibility study in Australia and was approved by the Australian Therapeutic Goods Administration (TGA) to initiate the next phase of the trial in two participating sites. The Science Park Administration in Taiwan approved ABVC’s plan to set up a pilot Good Manufacturing Practice (GMP) facility to produce Vitargus® and to pursue the process development work for manufacturing optimization. This project is proposed by ABVC’s Taiwan affiliate and co-development partner, BioFirst Corporation. The Phase II trial of Vitargus is expected to release its results in Q4 2023. If the results are positive, it could lead to distribution agreements in Asia and Australia in early 2024. According to iHealthcare Analyst, Inc., the global market for retinal surgery devices is expected to reach $4.3 billion by 2029, driven, in part, by the rising geriatric population worldwide.
FDA approves clinical trial of BLEX 404 for advanced non-small cell lung cancer
The US FDA has approved the Investigational New Drug (IND) application for the proposed clinical investigation of BLEX 404, the primary active ingredient in ABV-1519. This treatment is being co-developed by BioKey, Inc. and by the Rgene Corporation, Taiwan. The study is under review at the Taiwan FDA for approval. With three previous INDs approved by the US FDA for combination therapies of triple-negative breast cancer, myelodysplastic syndromes (MDS), and pancreatic cancer, BLEX 404 is a promising new option in the fight against cancer.
Here's a link for more information: Link
In conclusion
ABVC Biopharma Inc. is a promising investment with multiple near-term catalysts. The company’s strategic partnerships in neurological and mental health treatments create a promising future. ABVC’s CNS drugs targeting MDD and ADHD have definitive agreements with Xinnovation for ABV-1504, ABV-1505 and ABV-1601, Thedefinitive agreement carries a possible aggregate income of $20 million for ABVC. There is also a licensing deal with AiBtl BioPharma for a valuation of $667 million. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032. ABVC’s CNS has been developed into a controlled-release tablet formulation or PDC-1421, the primary active ingredient in its neurological programs. This formulation enables the active ingredient to be absorbed slower over time compared to conventional tablet formulations, thereby reducing the dosage frequency and increasing the bioavailability.
Investors should keep an eye on ABVC’s major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD) trials, which, if successful, will take the company closer to Phase III trials for those products and drive its multi-product biopharma company forward. The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials. At the same time, ABVC has commenced ADHD Phase IIb trials at the University of California, San Francisco (UCSF) and another five sites in Taiwan. With all these developments in place, ABVC Biopharma Inc. is poised to make a significant impact in the biopharmaceutical industry.
17000 share bid 500 ask $$$$$$$$$$$$$
Good place to begin trickling back in!!!????!!!!.... Would like some sub $1.05s but too much here that is good!
yep im a new investor. 5 mil mrket cap. got 7 mil in cash for deal plus up to over 600 mil more. ya im in for ride up$$$. 1x sales is over 120x up..
i like way its going up strong and slow. who would sell down here?? ill sell when over $100
Let's see a $1.50 + close. ABVC attracting new investors.
$7 mil in cash up front and 46 mil shares of co stock. great starting point . UP UP AND AWAY $$$$$$$$
this is what we want moving up slowly not 200% in one day than down 200%.
WOOOOOOOOOOOOW 21000 SHARE BUY @1.58 $$$$$$$$$$$$$$$$$$$$$$$
LOL!!!!! 4 million OS, Is that Small? Seems Small for a company receiving $7million up front (for Finalization of Product) in a royalty agreement valued > $500 Million
only 2 mil in float. 3 mil issued shares. 7 million up front is more than whole market cap of 5 mil. high is $18 $18 here we come.
664 mil is up 200x from here. lets buy whole co for 7 mil now $$$$$$$
667 million $ is 100x uppppppppppp from here $$$$$$$$$$$$$$$
1.85 FROM 1.21= NICE POP
Agree! A surge in revenue growth + surge of forward looking investors. ABVC is a great $$$$$ opportunity.
biggest deal in co history and if they get 200 mil thats 40x from here on 1x sales $$$$$$$$$
its going up again tomorrow. hopefully not so fast. let it run for weeks. $$$$$$$$$$$$
> $167,000,000. < 2.28 M share float < 52 week high 18.70 > Company revenue surge in the works!
Biggest volume day in company history.
guys stock 3x today. people r going to take a profit. going back up tommorrow $$$$$$
co got 150% of their market cap after big gain. stock will be much higher tomorrow. $$$$$$$$
up up and away. i just bought a bunch
Yea bro it was just a pump and dump I believe. Maybe an offering tomorrow wipe the rest of the share holders out.
WOW 1.20'S WHAT AN UGLY GAP & TRAP
ONLY SHORTS AND FUNDERS MAKING $$$ HERE
MOST RETAIL RED AF
ABVC & SFR
P&D'S
thnx, Who knows!?! down $200 now.....
Well good luck with that
Good Thinking, looks like. Bought 1k for a possible profit tomorrow. We'll See!!!1
Don’t know bro took huge loss moved on. Don’t care for a company after I lose money on it.
HMMMM! Smacked it under $1.50. The Deal included $7 million up front with a royalty agreement. Sounds Legit that no Equity involved, nor needed....
Maybe offering coming screw even more folks.
Yup fooled a bunch of people. Hate these plays. Trash
Followers
|
13
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
277
|
Created
|
02/28/08
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |